Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cardiomyopathy, Hypertrophic: later-stage trial registry
1 of 7 indexed Cardiomyopathy, Hypertrophic trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 1 currently recruiting · #2,497 of 28,707 conditions by registered trial count
Cardiomyopathy, Hypertrophic: 7 US clinical trials tracked, 1 recruiting.
Cardiomyopathy, Hypertrophic is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Bristol-Myers Squibb, running 2 of these trials.
Enrollment posture brief
Registry condition cardiomyopathy-hypertrophic
OPEN 1 | RECR 14% | LATE 2 | EARLY 0 | RANK #2497 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adverse Drug Events (14% recruiting · 7 trials)
Cardiomyopathy, Hypertrophic lists 1 open slots (14% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Cardiomyopathy, Hypertrophic on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Cardiomyopathy, Hypertrophic is recruiting below its size-band peers.
1 of 7 indexed trials (14.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Cardiomyopathy, Hypertrophic research.
Bristol-Myers Squibb accounts for 2 of 7 trials (28.6%). 6 distinct sponsors appear on at least one study for this condition label.
-
Typical Cardiomyopathy, Hypertrophic enrolment sits around 87 participants.
Median target enrolment is 87 among the 7 trials that report a genuine target (sentinel values excluded). 4 of those (57.1%) plan for fewer than 100 participants.
-
Cardiomyopathy, Hypertrophic splits between interventional and observational designs.
3 interventional and 4 observational studies make up this index (42.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
Columbia University
NCT06034405
A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Bristol-Myers Squibb
NCT06112743
A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Bristol-Myers Squibb
NCT06253221
Effects of Highly Active Anti-Retroviral Therapy on Cardiovascular Health in Infants of HIV-Infected Mothers
University of Miami
NCT00253682
Study of Exercise Training in Hypertrophic Cardiomyopathy
University of Michigan
NCT01127061
The Impact of Exercise-Induced Cardiac Remodeling on Myocardial Efficiency
Massachusetts General Hospital
NCT04580693
Study of Muscle Abnormalities in Patients With Specific Genetic Mutations
National Heart, Lung, and Blood Institute (NHLBI)
NCT00001871
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Cardiomyopathy, Hypertrophic records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Cardiomyopathy, Hypertrophic trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Cardiomyopathy, Hypertrophic page
7 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Cardiomyopathy, Hypertrophic trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Bristol-Myers Squibb sponsors the most Cardiomyopathy, Hypertrophic trials on record, review their full trial history before evaluating a specific study. See Bristol-Myers Squibb's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cardiomyopathy, Hypertrophic condition card totals 7 registered trials; most-linked intervention Mavacamten; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.